What is ISOThrive?
ISOThrive Inc. is a clinical-stage biotechnology firm dedicated to developing microbiome therapeutics for chronic diseases stemming from dysbiosis. The company's core innovation lies in its proprietary digestion-resistant carbohydrates, specifically maltosyl-isomaltooligosaccharide (MIMO), engineered to selectively target and bolster beneficial gut bacteria, thereby correcting microbial imbalances. Their lead therapeutic candidate, ISOT-101, is currently undergoing Phase 2 clinical trials, with initial indications focusing on gastrointestinal conditions such as GERD, IBS-C, and functional dyspepsia. ISOThrive leverages advanced platforms for accelerated carbohydrate drug discovery and precision medicine, aiming to deliver personalized therapeutic solutions for complex gastrointestinal disorders.
How much funding has ISOThrive raised?
ISOThrive has raised a total of $1.4M across 1 funding round:
Unspecified
$1.4M
Unspecified (2014): $1.4M, investors not publicly disclosed
What's next for ISOThrive?
With a substantial enterprise-level funding context, ISOThrive appears poised for significant scaling and advancement of its therapeutic pipeline. The recent major strategic investment likely signals confidence from backers in the company's technology and its potential to address unmet needs in chronic disease management. Future endeavors will likely concentrate on progressing ISOT-101 through its clinical development phases, potentially expanding its therapeutic indications, and further validating their rapid carbohydrate drug discovery platform. This strategic capital infusion is critical for navigating the rigorous demands of late-stage clinical trials and preparing for potential commercialization, solidifying ISOThrive's position in the competitive microbiome therapeutics market.
See full ISOThrive company page
